Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant

Bibliography

• Osoba D, Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997;5(4):307-13
   PubMedGoogle Scholar
• Leibundgut U, Lancranjan I. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet 1987;1(8543):1198
   PubMed Web of Science ®Google Scholar
• de Boer-Dennert M, Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997;76(8):1055-61
   PubMed Web of Science ®Google Scholar
• Olver I, A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol 1996;7(9):945-52
   PubMed Web of Science ®Google Scholar
• Diemunsch P, Grelot L. Potential of substance P antagonists as antiemetics. Drugs 2000;60(3):533-46
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21(22):4112-9
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97(12):3090-8
   PubMed Web of Science ®Google Scholar
• Chawla SP, Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97(9):2290-300
   PubMed Web of Science ®Google Scholar
• EMEND product information. Whitehouse Station, N.J., 08889 USA; MERCK & CO., Inc; 2006
   Google Scholar
• Bergstrom M, Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 2004;55(10):1007-12
   PubMed Web of Science ®Google Scholar
• Majumdar AK, Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol 2006;46(3):291-300
   PubMed Web of Science ®Google Scholar
• Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 2008;112(9):2080-7
   PubMed Web of Science ®Google Scholar
• Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs 2007;16(12):1977-85
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(6):549-58
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Clin Pharmacokinet 2005;44(6):637-47
   PubMed Web of Science ®Google Scholar
• Sanchez RI, Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004;32(11):1287-92
   PubMed Web of Science ®Google Scholar
• de Jonge ME, Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005;56(4):370-8
   PubMed Web of Science ®Google Scholar
• Jarkowski A. Possible contribution of aprepitant to ifosfamide-induced neurotoxicity. Am J Health Syst Pharm 2008;65(23):2229-31
   PubMed Web of Science ®Google Scholar
• Nygren P, Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005;55(6):609-16
   PubMed Web of Science ®Google Scholar
• Loos WJ, Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 2007;59(3):407-12
   PubMed Web of Science ®Google Scholar
• Depre M, Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005;61(5-6):341-6
   PubMed Web of Science ®Google Scholar
• Shadle CR, Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004;44(3):215-23
   PubMed Web of Science ®Google Scholar
• Blum RA, Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003;25(5):1407-19
   PubMed Web of Science ®Google Scholar
• Shah AK, Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr Med Res Opin 2005;21(4):595-601
   PubMed Web of Science ®Google Scholar
• McCrea JB, Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74(1):17-24
   PubMed Web of Science ®Google Scholar
• Kris MG, American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24(18):2932-47
   PubMed Web of Science ®Google Scholar
• Navari RM, Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 1999;340(3):190-5
   PubMed Web of Science ®Google Scholar
• Campos D, Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19(6):1759-67
   PubMed Web of Science ®Google Scholar
• de Wit R, Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21(22):4105-11
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17(6):1000-6
   PubMed Web of Science ®Google Scholar
• Oechsle K, Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone. Onkologie 2006;29(12):557-61
   PubMed Web of Science ®Google Scholar
• Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 2007;12(9):1143-50
   PubMed Web of Science ®Google Scholar
• Gore L, Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 2009;52(2):242-7
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100(10):2261-8
   PubMed Web of Science ®Google Scholar
• Warr DG, Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23(12):2822-30
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 2009
   Google Scholar
• Herrstedt J, Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104(7):1548-55
   PubMed Web of Science ®Google Scholar
• Jordan K, Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 2009;45(7):1184-7
   PubMed Web of Science ®Google Scholar
• Lordick F, Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer 2007;43(2):299-307
   PubMed Web of Science ®Google Scholar